Radiation exposure during radiofrequency catheter ablation of accessory atrioventricular connections.
Open Access
- 1 December 1991
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 84 (6) , 2376-2382
- https://doi.org/10.1161/01.cir.84.6.2376
Abstract
BACKGROUND Catheter ablation of accessory atrioventricular (AV) connections has been demonstrated to be effective in more than 85% of patients. One of the risks of this procedure is radiation exposure during the fluoroscopic imaging necessary to guide catheter manipulation. The objective of the present study was to measure the radiation received by patients and physicians during radiofrequency catheter ablation and to estimate the resultant somatic and genetic risks. METHODS AND RESULTS Radiation exposure to patients and physicians was measured during attempts at radiofrequency catheter ablation of accessory AV connections in 31 consecutive patients. Radiation exposure was measured using thermoluminescent sensors placed on the patient and on the physician. Somatic and genetic risks were estimated based on the radiation levels recorded using these sensors. The durations of fluoroscopy and of the catheter ablation procedure were recorded for each patient. Catheter ablation was successful in 28 of 31 patients (90%). Mean +/- SD duration of fluoroscopy was 44 +/- 40 minutes. The largest patient radiation dose was measured over the ninth vertebral body posteriorly (median, 7.26 rem [roentgen equivalents man]; range, 0.31-135.7 rem). Median radiation dose to the thyroid was 0.46 rem (range, 0.06-7.26 rem), and median radiation dose to the posterior iliac crest was 2.43 rem (range, 0.01-8.3 rem). The greatest radiation dose to the operator was recorded at the left hand (99 mrem). Mean radiation dose to the operator's eyes was 28 mrem. CONCLUSIONS Radiofrequency catheter ablation of accessory AV connections may result in significant radiation exposure to the patient and to the physician. Each hour of fluoroscopic imaging is associated with a lifetime risk of developing a fatal malignancy of 0.1% and a risk of a genetic defect of 20 per 1 million births. Although these risks must be recognized, they are relatively small compared with the risks associated with alternate approaches to management, including no therapy, antiarrhythmic drug therapy, and surgery.Keywords
This publication has 18 references indexed in Scilit:
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Surgery for the Wolff-Parkinson-White syndrome in 73 consecutive patients: what have we learnt from intraoperative mapping?European Journal of Cardio-Thoracic Surgery, 1989
- Surgical Division of Wolff-Parkinson-White Pathways Utilizing the Closed-Heart Technique: A 2-Year Experience in 47 PatientsThe Annals of Thoracic Surgery, 1988
- Cryoablation of the accessory pathway in Wolff-Parkinson-White syndrome: initial results and long term follow up.Heart, 1988
- The proarrhythmic effects of antiarrhythmic drugsAmerican Heart Journal, 1987
- Radiation exposure to patients undergoing percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1987
- AmiodaroneNew England Journal of Medicine, 1987
- The status of surgery for cardiac arrhythmias.Circulation, 1985
- Operator radiation exposure during percutaneous transluminal coronary angioplastyJournal of the American College of Cardiology, 1984
- Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs.Circulation, 1982